Foreign Language Versions Sample Clauses

Foreign Language Versions. The CMS has built in capabilities to host multiple foreign language versions of a specific County Department section of the Web Site. This feature shall be customizable to accommodate County-specific CMS foreign language business requirements, including workflow functionality or integration with an existing CMS used by the County or other 3rd party software solution.
Sample 1
AutoNDA by SimpleDocs
Foreign Language Versions. RFW shall be entitled to render production services to dub, subtitle, translate or have such additional changes made to Existing NTN Programs or Existing Non-NTN Programs for localization, censorship, time-editing or similar purposes to meet the requirements of Program licensors. RFW shall be entitled to reimbursement for the reasonable out-of-pocket costs for such dubbing, subtitling, translating or similar work, provided that PREVIEW TRAVEL pre-approves such costs and is provided reasonable substantiation of such costs in the form of invoices or other documentation. The dubbed, subtitled, translated or localized programs created pursuant to this Section 7 shall be deemed the "Foreign Language Versions" and shall be the sole property of PREVIEW TRAVEL as a work-made-for-hire specially ordered or commissioned by PREVIEW TRAVEL, with PREVIEW TRAVEL being deemed the sole author thereof and RFW hereby transfers and assigns all rights, title and interest therein, including all copyrights. RFW hereby waives and agrees never to assert any so-called moral rights therein and thereto and to execute all further documents reasonably requested by PREVIEW TRAVEL to further evidence, confirm or set of record PREVIEW TRAVEL's rights to the Foreign Language Versions of Existing NTN Programs or Existing Non-NTN Programs. RFW shall furnish broadcast-quality copies of the Foreign Language Versions to PREVIEW TRAVEL upon request at PREVIEW TRAVEL's expense for delivery and duplication.
Sample 1
Foreign Language Versions. If Producer has prepared versions of the ------------------------- Picture in any language in addition to English, Purchaser shall have unrestricted access to any such dubbed or subtitled tracks of the Picture without payment of a permission, use or performance fee (including residuals or any mechanical fees) by Purchaser to Producer or any third party (although Purchaser shall advance the cost of any orders for prints placed with the laboratory with respect to such dubbed or subtitled tracks).
Sample 1
Foreign Language Versions. 17.1. Distributor may make a subtitled/dubbed version of the Film in the Authorized Language, at Distributor’s sole costs and expense. Distributor shall seek and abide by all Licensor’s reasonable instructions in connection with the cost and preparation of the said dubbed and/or subtitled version of the Film, and shall strictly conform to all relevant restrictions applicable to artists and other third parties of which Licensor shall advise Distributor. Distributor shall not change or translate the title of the Film without the prior written consent of Licensor. Distributor shall also use exclusively and in its entirety the music which has been used in the original version of the Film. Distributor shall indemnify and hold Licensor harmless from any claims, loss, damage or expense (including reasonable legal fees and expenses) arising out of or in connection with the dubbing or subtitling of the Film.
Sample 1
Foreign Language Versions. If Licensor, or any distributor or licensee of Licensor, has prepared or subsequently prepares versions of the Miniseries in any language version, CPT shall have unrestricted access to any such dubbed or subtitled tracks of the Miniseries without payment of a permission, use or performance fee (including residuals or any mechanical fees) by CPT to Licensor or any third party (although CPT shall advance the cost of any orders for masters placed with the laboratory with respect to such dubbed or subtitled tracks).
Sample 1

Related to Foreign Language Versions

  • Languages 20.1 The Proclamation of Sale, these conditions of sale and the Memorandum may have been translated and published in different forms and languages. In the event of any discrepancy, misstatement, omission or error appearing in the various forms or languages, this English version shall prevail.

  • VERSION Each Quote will be governed under the version of this Agreement that is in place as of the “last updated” date indicated at the bottom of this document. For that reason, you should keep a copy of this document and make a note of the date indicated below when you accept a Quote.

  • Official Language The official text of this Agreement and any appendices, exhibits and schedules hereto, or any notice given or accounts or statements required by this Agreement shall be in English. In the event of any dispute concerning the construction or meaning of this Agreement, reference shall be made only to this Agreement as written in English and not to any other translation into any other language.

  • Language and Copies This Agreement is written in Chinese and English and both the English version and Chinese version shall have the same effect. This Agreement is executed in 3 copies for each version and each original copy has the same legal effect.

  • English Language (a) Any notice given under or in connection with any Finance Document must be in English.

  • Regulatory Applications (a) Sky and SBI and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare, within 45 days of the execution of this Agreement, all documentation and requests for regulatory approval, to timely effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities and Regulatory Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Sky and SBI shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, and shall be provided in advance so as to reasonably exercise its right to review in advance, all material written information submitted to any third party or any Governmental Authority or Regulatory Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities or Regulatory Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.

  • Translations In the event of any discrepancy, misstatement, omission or error appearing in the various translations on the particulars and condition herein, the English version shall prevail.

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Use of English Language This Agreement has been executed and delivered in the English language. Any translation of this Agreement into another language shall have no interpretive effect. All documents or notices to be delivered pursuant to or in connection with this Agreement shall be in the English language or, if any such document or notice is not in the English language, accompanied by an English translation thereof, and the English language version of any such document or notice shall control for purposes thereof.

  • General Application The rules set forth below in this Article IV shall apply for the purposes of determining each Member’s general allocable share of the items of income, gain, loss or expense of the Company comprising Net Income or Net Loss of the Company for each Fiscal Year, determining special allocations of other items of income, gain, loss and expense, and adjusting the balance of each Member’s Capital Account to reflect the aforementioned general and special allocations. For each Fiscal Year, the special allocations in Section 4.4 shall be made immediately prior to the general allocations of Section 4.3.

Time is Money Join Law Insider Premium to draft better contracts faster.